Status:
UNKNOWN
Identification of Broadly HIV-1 Neutralizing Antibodies (bNAb) in HIV-infected Patients in Mbeya, Tanzania.
Lead Sponsor:
Michael Hoelscher
Collaborating Sponsors:
National Institute for Medical Research - Mbeya Medical Research Centre (NIMR-MMRC)
University Clinic of Cologne, Department of Internal Medicine, Center for Molecular Medicine Cologne (CMMC)
Conditions:
HIV/AIDS
Eligibility:
All Genders
18+ years
Brief Summary
In natural HIV disease, a small fraction (1-2%) of infected individuals develops exceptionally high titres of HIV-1 neutralizing serum activity. Antibodies isolated from these individuals have been sh...
Eligibility Criteria
Inclusion
- Voluntary and informed consent
- ≥18 years of age
- Documented HIV infection.
- Willing to consent to active tracing including home tracing
Exclusion
- Deficiency, rendering it difficult, if not impossible, to take part in the study or understand the information provided. This includes alcoholism, drug dependency as well as psychiatric illnesses, suicidal tendencies or any other inability.
- Prisoners
- If within the discretion of the investigator study participation would possibly add not acceptable risk or burden to patient (e.g. significant health deficiencies, social harm)
- Unlikely to comply with protocol as judged by the principal investigator or his designate
Key Trial Info
Start Date :
October 15 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2024
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT03334552
Start Date
October 15 2017
End Date
August 1 2024
Last Update
November 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NIMR-Mbeya Medical Research Center (MMRC)
Mbeya, Tanzania